<html><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta http-equiv="Content-Style-Type" content="text/css" /><meta name="generator" content="Aspose.Words for .NET 13.4.0.0" /><title>Health Select Committee:_x000b_Public expenditure on health and social care</title></head><body><div><p style="margin:0pt"><span style="font-family:Arial; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 10pt; text-align:center; text-indent:7.1pt"><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">Written evidence from the Royal College of Pathologists (PEX 0019)</span></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:0pt"><tr><td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:462.1pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">&#xa0;</span></p><p style="font-size:12pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">Summary of The Royal College of Pathologists’ written submission</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:12pt; margin:0pt 0pt 0pt 28.52pt; padding-left:7.48pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:12pt">In this submission </span><span style="font-family:'Times New Roman'; font-size:12pt">The </span><span style="font-family:'Times New Roman'; font-size:12pt">Royal College of Pathologists</span><span style="font-family:'Times New Roman'; font-size:12pt"> (RCPath</span><span style="font-family:'Times New Roman'; font-size:12pt">)</span><span style="font-family:'Times New Roman'; font-size:12pt"> focusses on where efficiency gains can be made, where money could be wasted </span><span style="font-family:'Times New Roman'; font-size:12pt">and </span><span style="font-family:'Times New Roman'; font-size:12pt">where the best outcome for patients might be put at risk.</span></li></ul><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:12pt; margin:0pt 0pt 0pt 28.52pt; padding-left:7.48pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:12pt">Pathology is a major clinical service and is involved in most clinical interventions. It drives most healthcare </span><span style="font-family:'Times New Roman'; font-size:12pt">decisions and is a core component in 70 per cent of clinical interventions (diagnosis, choice of treat</span><span style="font-family:'Times New Roman'; font-size:12pt">ment, efficacy of treatment). </span><span style="font-family:'Times New Roman'; font-size:12pt">Demand across virtually all disciplines of pathology has been rising at an average of 10 per cent per annum between 2003-200</span><span style="font-family:'Times New Roman'; font-size:12pt">6 (latest available figures).</span></li></ul><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:12pt; margin:0pt 0pt 0pt 28.52pt; padding-left:7.48pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:12pt">The Carter Review suggested that savings of between 10</span><span style="font-family:'Times New Roman'; font-size:12pt">%</span><span style="font-family:'Times New Roman'; font-size:12pt"> and 20</span><span style="font-family:'Times New Roman'; font-size:12pt">%</span><span style="font-family:'Times New Roman'; font-size:12pt"> could be achieved through the reconfiguration and consolidation of pathology services. At a national level, this would imply annual savings of £250 </span><span style="font-family:'Times New Roman'; font-size:12pt">- </span><span style="font-family:'Times New Roman'; font-size:12pt">£500 millio</span><span style="font-family:'Times New Roman'; font-size:12pt">n in total, based on figures for 2005.</span></li></ul><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">Requests for pathology tests and services are variable</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:12pt; margin:0pt 0pt 0pt 28.52pt; padding-left:7.48pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:12pt">The </span><span style="font-family:'Times New Roman'; font-size:12pt; font-style:italic">Diagnostic Atlas of Variation</span><span style="font-family:'Times New Roman'; font-size:12pt"> uses audit data that collects information about the entire GP pathology workload reported within England. The data highlights huge differences in test requesting rates for commonly requested </span><span style="font-family:'Times New Roman'; font-size:12pt">tests, much of which cannot be </span><span style="font-family:'Times New Roman'; font-size:12pt">expl</span><span style="font-family:'Times New Roman'; font-size:12pt">ained by differences in patie</span><span style="font-family:'Times New Roman'; font-size:12pt">nt </span><span style="font-family:'Times New Roman'; font-size:12pt">case mix between primary care trusts or general practices. </span><span style="font-family:'Times New Roman'; font-size:12pt">While there may be other factors to explain some of the variation, t</span><span style="font-family:'Times New Roman'; font-size:12pt">he implication is that there are large instances of both over-requesting and under-requesting of pathology tests.</span></li></ul><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:12pt; margin:0pt 0pt 0pt 28.52pt; padding-left:7.48pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:12pt">Inappropria</span><span style="font-family:'Times New Roman'; font-size:12pt">te over-testing has substantial effects on financial expenditure, and may lead to significant damage to patient care with inappropriate investigations leading to inappropriate interpretation and indeed incorrect diagnoses. </span></li></ul><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:12pt; margin:0pt 0pt 0pt 28.52pt; padding-left:7.48pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:12pt">The diversion of much valued re</span><span style="font-family:'Times New Roman'; font-size:12pt">sources towards paying for unnecessary investigations means that the opportunity cost that could be used to accelerate much needed new developments and services is delayed or even lost. Under-requesting has similar effects with many patients missing out on</span><span style="font-family:'Times New Roman'; font-size:12pt"> much needed investigations resulting in missed or delayed diagnosis or management</span><span style="font-family:'Times New Roman'; font-size:12pt">.</span></li></ul><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:12pt; margin:0pt 0pt 0pt 28.52pt; padding-left:7.48pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:12pt">Regardless of whether the variation reveals over or under requesting, this variation reflects inefficient use of NHS resource and may indicate overall unacceptable levels </span><span style="font-family:'Times New Roman'; font-size:12pt">of health care. </span></li></ul><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">Pathology Demand Optimisation (PDO)</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:12pt; margin:0pt 0pt 0pt 28.52pt; padding-left:7.48pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:12pt">Pathology Demand Optimisation (demand management) is not a new concept in pathology services. It </span><span style="font-family:'Times New Roman'; font-size:12pt">is of vital importance to ensure the right test is done to the right patient at the right time, ensuring</span><span style="font-family:'Times New Roman'; font-size:12pt"> the best use of scarce NHS resource and the best </span><span style="font-family:'Times New Roman'; font-size:12pt">possible outcomes for patients. The RCPath continues to drive this process through initiatives such as the National Laboratory Medicine Catalogue to improve the sharing of pathology test results and the P</span><span style="font-family:'Times New Roman'; font-size:12pt">DO</span><span style="font-family:'Times New Roman'; font-size:12pt"> </span><span style="font-family:'Times New Roman'; font-size:12pt">guidance</span><span style="font-family:'Times New Roman'; font-size:12pt">.</span></li></ul><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:12pt; margin:0pt 0pt 0pt 28.52pt; padding-left:7.48pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:12pt">The RCPath initiative, with other pathology based organisations aims to define consistent guidance and tools to assist health care providers to minimise both under and over requesting. </span><span style="font-family:'Times New Roman'; font-size:12pt">An example of this is the development of guidance for </span><span style="font-family:'Times New Roman'; font-size:12pt">Mini</span><span style="font-family:'Times New Roman'; font-size:12pt">mum Retesting Interval</span><span style="font-family:'Times New Roman'; font-size:12pt">s</span><span style="font-family:'Times New Roman'; font-size:12pt"> (MRI). The use of MRIs is of vital importance and aims to define the minimum time interval whereby tests </span><span style="font-family:'Times New Roman'; font-size:12pt">can </span><span style="font-family:'Times New Roman'; font-size:12pt">be repeated. This avoids unnecessary repeat testing – a common problem in secondary care with laboratory tests frequently b</span><span style="font-family:'Times New Roman'; font-size:12pt">eing repeated whenever the patient crosses an interface of care, such as a ward transfer.</span></li></ul><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">Reconfiguration</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:12pt; margin:0pt 0pt 0pt 28.52pt; padding-left:7.48pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:12pt">The R</span><span style="font-family:'Times New Roman'; font-size:12pt">CPath </span><span style="font-family:'Times New Roman'; font-size:12pt">supports the development of consolidated networks for pathology services to help improve the quality and safety of patient care as outlin</span><span style="font-family:'Times New Roman'; font-size:12pt">ed in </span><span style="font-family:'Times New Roman'; font-size:12pt; font-style:italic">The Report of the Second Phase of the Review of NHS Pathology Services in England</span><span style="font-family:'Times New Roman'; font-size:12pt">, </span><span style="font-family:'Times New Roman'; font-size:12pt">December 2008</span><span style="font-family:'Times New Roman'; font-size:12pt">.</span></li></ul><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:12pt; margin:0pt 0pt 0pt 28.52pt; padding-left:7.48pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:12pt">However, the College thinks that picture today is radically different from Lord Carter’s vision; far from a service that is integrated and patient-centred the commissioning process </span><span style="font-family:'Times New Roman'; font-size:12pt">has </span><span style="font-family:'Times New Roman'; font-size:12pt">so far been driven by financial considerations. </span></li></ul><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:12pt; margin:0pt 0pt 0pt 28.52pt; padding-left:7.48pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:12pt">The College has warne</span><span style="font-family:'Times New Roman'; font-size:12pt">d that that there will be a detrimental effect on services from failed reconfigurations, as well as high cost</span><span style="font-family:'Times New Roman'; font-size:12pt">s</span><span style="font-family:'Times New Roman'; font-size:12pt"> incurred.</span></li></ul><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p></td></tr></table><p style="margin:0pt 0pt 0pt 28.35pt; text-align:justify; text-indent:-28.35pt"><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">1</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">About The Royal College of Pathologists</span></p><p style="margin:0pt 0pt 0pt 28.35pt; text-align:justify; text-indent:-28.35pt"><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 28.35pt; text-align:justify; text-indent:-28.35pt"><span style="font-family:'Times New Roman'; font-size:12pt">1.1</span><span style="font-family:'Times New Roman'; font-size:12pt">              </span><span style="font-family:'Times New Roman'; font-size:12pt">The Royal College of Pathologists (RCPath) is a professional membership organisation with charitable status. It is committed to setting and maintaining professional standards and to promoting excellence in the teaching and practice of pathology. </span><span style="font-family:'Times New Roman'; font-size:12pt">Pathology </span><span style="font-family:'Times New Roman'; font-size:12pt">is the science at the heart of modern medicine and is </span><span style="font-family:'Times New Roman'; font-size:12pt">a core component in 70</span><span style="font-family:'Times New Roman'; font-size:12pt">%</span><span style="font-family:'Times New Roman'; font-size:12pt"> of clinical interventions (di</span><span style="font-family:'Times New Roman'; font-size:12pt">agnosis, </span><span style="font-family:'Times New Roman'; font-size:12pt">choice of treatment, efficacy of treatment)</span><span style="font-family:'Times New Roman'; font-size:12pt">. The College aims to advance the science and practice of pathology, to provide public education,</span><span style="font-family:'Times New Roman'; font-size:12pt"> to promote research in pathology and to disseminate the results. We have members across 19 </span><span style="font-family:'Times New Roman'; font-size:12pt">specialties </span><span style="font-family:'Times New Roman'; font-size:12pt">working in hospital laboratories, universities and industry worldwide to diagnose, treat and prevent illness.</span></p><p style="margin:6pt 0pt 0pt 28.35pt; text-align:justify; text-indent:-28.35pt"><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">2</span><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">              </span><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">Introduction</span></p><p style="margin:0pt 0pt 0pt 28.35pt; text-align:justify; text-indent:-28.35pt"><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 28.35pt; text-align:justify; text-indent:-28.35pt"><span style="font-family:'Times New Roman'; font-size:12pt">2.1</span><span style="font-family:'Times New Roman'; font-size:12pt">              </span><span style="font-family:'Times New Roman'; font-size:12pt">In this submission </span><span style="font-family:'Times New Roman'; font-size:12pt">the </span><span style="font-family:'Times New Roman'; font-size:12pt">RCPath focusses on where efficiency ga</span><span style="font-family:'Times New Roman'; font-size:12pt">ins can be made and where there </span><span style="font-family:'Times New Roman'; font-size:12pt">is a risk of money being wasted.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 28.35pt; text-align:justify; text-indent:-28.35pt"><span style="font-family:'Times New Roman'; font-size:12pt">2.2</span><span style="font-family:'Times New Roman'; font-size:12pt">              </span><span style="font-family:'Times New Roman'; font-size:12pt">Pathology is a major clinical service and is involved in most clinical interventions. </span><span style="font-family:'Times New Roman'; font-size:12pt">It drives most </span><span style="font-family:'Times New Roman'; font-size:12pt">healthcare decisions</span><span style="font-family:'Times New Roman'; font-size:12pt"> and is a core componen</span><span style="font-family:'Times New Roman'; font-size:12pt">t in 70</span><span style="font-family:'Times New Roman'; font-size:12pt">%</span><span style="font-family:'Times New Roman'; font-size:12pt"> of clinical interventions (diagnosis, choice of treatment, efficacy of treatment). </span><span style="font-family:'Times New Roman'; font-size:12pt">It employs 25,000 staff and costs the NHS in the order of £2.5 billi</span><span style="font-family:'Times New Roman'; font-size:12pt">on a year, representing nearly </span><span style="font-family:'Times New Roman'; font-size:12pt">4%</span><span style="font-family:'Times New Roman'; font-size:12pt"> of total NHS expenditure.</span><span style="font-family:'Times New Roman'; font-size:12pt"> </span><span style="font-family:'Times New Roman'; font-size:12pt">Demand across virtually all discipli</span><span style="font-family:'Times New Roman'; font-size:12pt">nes of pathology has been rising at an average of 10</span><span style="font-family:'Times New Roman'; font-size:12pt">%</span><span style="font-family:'Times New Roman'; font-size:12pt"> per annum between 2003-2006 (latest available figures).</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 28.35pt; text-align:justify; text-indent:-28.35pt"><span style="font-family:'Times New Roman'; font-size:12pt">2.3</span><span style="font-family:'Times New Roman'; font-size:12pt">              </span><span style="font-family:'Times New Roman'; font-size:12pt; font-style:italic">The </span><span style="font-family:'Times New Roman'; font-size:12pt; font-style:italic">Report of the Second Phase of the Review of NHS Pat</span><span style="font-family:'Times New Roman'; font-size:12pt; font-style:italic">hology Services in England</span><span style="font-family:'Times New Roman'; font-size:12pt"> (The </span><span style="font-family:'Times New Roman'; font-size:12pt">Carter Review) suggested that savings of between 10</span><span style="font-family:'Times New Roman'; font-size:12pt">%</span><span style="font-family:'Times New Roman'; font-size:12pt"> a</span><span style="font-family:'Times New Roman'; font-size:12pt">nd 20</span><span style="font-family:'Times New Roman'; font-size:12pt">%</span><span style="font-family:'Times New Roman'; font-size:12pt"> could be achieved through the reconfiguration and consolidation of pathology services. At a national level, this would imply annual savings of £250 </span><span style="font-family:'Times New Roman'; font-size:12pt">-</span><span style="font-family:'Times New Roman'; font-size:12pt"> £500 million in total, based on figures for 2005.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 28.35pt; text-align:justify; text-indent:-28.35pt"><span style="font-family:'Times New Roman'; font-size:12pt">2.4</span><span style="font-family:'Times New Roman'; font-size:12pt">              </span><span style="font-family:'Times New Roman'; font-size:12pt">The </span><span style="font-family:'Times New Roman'; font-size:12pt">RCPath welcomes this opportunity to </span><span style="font-family:'Times New Roman'; font-size:12pt">submit evidence to the Health Select Committee on this important issue.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 28.35pt; text-align:justify; text-indent:-28.35pt"><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">3.</span><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">              </span><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">Evidence that </span><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">requests for </span><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">pathology tests and services </span><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">are </span><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">variable</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 28.35pt; text-align:justify; text-indent:-28.35pt"><span style="font-family:'Times New Roman'; font-size:12pt">3.1</span><span style="font-family:'Times New Roman'; font-size:12pt">              </span><span style="font-family:'Times New Roman'; font-size:12pt">The increasing importance of pathology in relation to healthcare cannot be overstated. </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 28.35pt; text-align:justify; text-indent:-28.35pt"><span style="font-family:'Times New Roman'; font-size:12pt">3.2</span><span style="font-family:'Times New Roman'; font-size:12pt">              </span><span style="font-family:'Times New Roman'; font-size:12pt">There has been a large rise in requests for pathology tests over the past decade, with the not unexpected associated effect on expenditure. Much of this rise seen in pathology test use is justified, and can be related to the development of new clinical gui</span><span style="font-family:'Times New Roman'; font-size:12pt">dance, patient pathways, health screening initiatives, Quality Outcomes Framework (QOF) targets and the availability of new, more useful tests – especially in the field of </span><span style="font-family:'Times New Roman'; font-size:12pt">molecular pathology.</span><span style="font-family:'Times New Roman'; font-size:12pt"> </span></p><p style="margin:0pt 0pt 0pt 28.35pt; text-align:justify; text-indent:-28.35pt"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 28.35pt; text-align:justify; text-indent:-28.35pt"><span style="font-family:'Times New Roman'; font-size:12pt">3.3</span><span style="font-family:'Times New Roman'; font-size:12pt">              </span><span style="font-family:'Times New Roman'; font-size:12pt">There are a number of reasons </span><span style="font-family:'Times New Roman'; font-size:12pt">why </span><span style="font-family:'Times New Roman'; font-size:12pt">demand for pathology services </span><span style="font-family:'Times New Roman'; font-size:12pt">is </span><span style="font-family:'Times New Roman'; font-size:12pt">likely to continue to rise:</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:12pt; margin:0pt 0pt 0pt 38.87pt; padding-left:17.83pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:12pt">Chronic disease accounts for around 50</span><span style="font-family:'Times New Roman'; font-size:12pt">%</span><span style="font-family:'Times New Roman'; font-size:12pt"> of all pathology activity; with an ageing population, there is likely to be a corresponding increase in chronic disease, such as heart disease, chronic re</span><span style="font-family:'Times New Roman'; font-size:12pt">spiratory diseases, and a greater demand for pathology services</span><span style="font-family:'Times New Roman'; font-size:12pt">.</span></li></ul><p style="margin:0pt 0pt 0pt 56.7pt; text-align:justify; text-indent:-28.35pt"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="background-color:#ffffff; font-family:Symbol; font-size:12pt; line-height:13.5pt; margin:0pt 0pt 13.5pt 38.87pt; padding-left:17.83pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:12pt">An increasing trend towards personalised medicine using molecular-based investigations; for example</span><span style="font-family:'Times New Roman'; font-size:12pt">, in</span><span style="font-family:'Times New Roman'; font-size:12pt"> the study of specimens taken from cancer patients the pathologist can test the specime</span><span style="font-family:'Times New Roman'; font-size:12pt">n to determine where the cancer originated, and to look for</span><span style="font-family:'Times New Roman'; font-size:12pt"> </span><span style="font-family:'Times New Roman'; font-size:12pt">markers</span><span style="font-family:'Times New Roman'; font-size:12pt"> which could indicate susceptibility to specific cancer treatments. For example, a breast cancer </span><span style="font-family:'Times New Roman'; font-size:12pt">that </span><span style="font-family:'Times New Roman'; font-size:12pt">is </span><span style="font-family:'Times New Roman'; font-size:12pt">o</span><span style="font-family:'Times New Roman'; font-size:12pt">estrogen sensitive will be treated differently </span><span style="font-family:'Times New Roman'; font-size:12pt">from </span><span style="font-family:'Times New Roman'; font-size:12pt">a breast cancer </span><span style="font-family:'Times New Roman'; font-size:12pt">that </span><span style="font-family:'Times New Roman'; font-size:12pt">is not. Us</span><span style="font-family:'Times New Roman'; font-size:12pt">ing </span><span style="font-family:'Times New Roman'; font-size:12pt">molecular pathology</span><span style="font-family:'Times New Roman'; font-size:12pt">, an</span><span style="font-family:'Times New Roman'; font-size:12pt"> oncologist </span><span style="font-family:'Times New Roman'; font-size:12pt">can develop a treatment approach </span><span style="font-family:'Times New Roman'; font-size:12pt">that </span><span style="font-family:'Times New Roman'; font-size:12pt">is tailored to the patient.</span></li></ul><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:12pt">3.4</span><span style="font-family:'Times New Roman'; font-size:12pt">              </span><span style="font-family:'Times New Roman'; font-size:12pt">There is also evidence that shows </span><span style="font-family:'Times New Roman'; font-size:12pt">a </span><span style="font-family:'Times New Roman'; font-size:12pt">considerable level of inappropriate requesting</span><span style="font-family:'Times New Roman'; font-size:12pt"> -</span><span style="font-family:'Times New Roman'; font-size:12pt"> some have estimated this to be anywhere between </span><span style="font-family:'Times New Roman'; font-size:12pt">5%</span><span style="font-family:'Times New Roman'; font-size:12pt"> and 98</span><span style="font-family:'Times New Roman'; font-size:12pt">% (</span><span style="font-family:'Times New Roman'; font-size:12pt">Van Walraven C, Naylor CD. </span><span style="font-family:'Times New Roman'; font-size:12pt; font-style:italic">Do we know what inappropriate laboratory utilization is? A systematic review of laboratory clinical audits</span><span style="font-family:'Times New Roman'; font-size:12pt">. JAMA 1998; 280: 550-</span><span style="font-family:'Times New Roman'; font-size:12pt">55</span><span style="font-family:'Times New Roman'; font-size:12pt">8).</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:12pt">3.5</span><span style="font-family:'Times New Roman'; font-size:12pt">              </span><span style="font-family:'Times New Roman'; font-size:12pt">Many benchmarking studies have been carried out looking at the variation in laboratory test ordering between countries, regions and individual hospital wards or general practices. </span><span style="font-family:'Times New Roman'; font-size:12pt; font-style:italic">The Diagnostic Atlas of Variation</span><span style="font-family:'Times New Roman'; font-size:12pt"> uses audit data that collects information </span><span style="font-family:'Times New Roman'; font-size:12pt">about the entire GP pathology workload reported within England. The data highlights huge differences in test requesting rates for commonly requested </span><span style="font-family:'Times New Roman'; font-size:12pt">tests, much of which cannot be </span><span style="font-family:'Times New Roman'; font-size:12pt">expl</span><span style="font-family:'Times New Roman'; font-size:12pt">ained by differences in patient </span><span style="font-family:'Times New Roman'; font-size:12pt">case mix between primary care trusts or </span><span style="font-family:'Times New Roman'; font-size:12pt">general practices. </span><span style="font-family:'Times New Roman'; font-size:12pt">While there may be other factors to explain </span><span style="font-family:'Times New Roman'; font-size:12pt">some of the variation, t</span><span style="font-family:'Times New Roman'; font-size:12pt">he implication is that there are large instances of both over-requesting and under-requesting of pathology tests.</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:12pt">3.6</span><span style="font-family:'Times New Roman'; font-size:12pt">              </span><span style="font-family:'Times New Roman'; font-size:12pt">While this may be down to variable knowledge of ho</span><span style="font-family:'Times New Roman'; font-size:12pt">w to b</span><span style="font-family:'Times New Roman'; font-size:12pt">est use laboratory tests among</span><span style="font-family:'Times New Roman'; font-size:12pt"> GPs, there is also the problem of specific test availability, with an effective “diagnostics by postcode” system in place</span><span style="font-family:'Times New Roman'; font-size:12pt">. This means</span><span style="font-family:'Times New Roman'; font-size:12pt"> that some of the newer tests are not available at all in some regions of the country </span><span style="font-family:'Times New Roman'; font-size:12pt">due to cost or lack of awareness</span><span style="font-family:'Times New Roman'; font-size:12pt">. An example of this is</span><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold"> </span><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:normal">B-type natriuretic peptide</span><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold"> </span><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:normal">testing for heart failure, where there is patchy use ranging from high to none at all.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:12pt">3.7</span><span style="font-family:'Times New Roman'; font-size:12pt">              </span><span style="font-family:'Times New Roman'; font-size:12pt">Inappropriate over-testing has significant effects on financial expenditure, not only on the direct cost to the laboratory, but also as a result of the costs of subsequent </span><span style="font-family:'Times New Roman'; font-size:12pt">unnecessary, knock-</span><span style="font-family:'Times New Roman'; font-size:12pt">on investigations that may be ordered following the inevitable fa</span><span style="font-family:'Times New Roman'; font-size:12pt">lse positive result. The damage to patient care may</span><span style="font-family:'Times New Roman'; font-size:12pt">,</span><span style="font-family:'Times New Roman'; font-size:12pt"> however</span><span style="font-family:'Times New Roman'; font-size:12pt">,</span><span style="font-family:'Times New Roman'; font-size:12pt"> be even more significant, with inappropriate investigations leading to inappropriate interpretation and indeed incorrect diagnoses. In addition, the diversion of much valued resources towards pa</span><span style="font-family:'Times New Roman'; font-size:12pt">ying for unnecessary investigations means that the opportunity cost that could be used to accelerate much needed new developments and services is delayed or even lost. Under-requesting has similar effects with many patients missing out on much needed inves</span><span style="font-family:'Times New Roman'; font-size:12pt">tigations</span><span style="font-family:'Times New Roman'; font-size:12pt">,</span><span style="font-family:'Times New Roman'; font-size:12pt"> resulting in missed or delayed diagnosis or management.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:12pt">3.8</span><span style="font-family:'Times New Roman'; font-size:12pt">              </span><span style="font-family:'Times New Roman'; font-size:12pt">Patients rely on their GP</span><span style="font-family:'Times New Roman'; font-size:12pt">s</span><span style="font-family:'Times New Roman'; font-size:12pt"> to request the right tests to correctly diagnose and monitor a range of health conditions</span><span style="font-family:'Times New Roman'; font-size:12pt">, such as diabetes or heart disease</span><span style="font-family:'Times New Roman'; font-size:12pt">. GPs also use a range of tests t</span><span style="font-family:'Times New Roman'; font-size:12pt">o screen people at risk of a disease </span><span style="font-family:'Times New Roman'; font-size:12pt">even where there</span><span style="font-family:'Times New Roman'; font-size:12pt"> is no evidence of the disease. The National Institute for Health </span><span style="font-family:'Times New Roman'; font-size:12pt">and </span><span style="font-family:'Times New Roman'; font-size:12pt">Care Excellence (NICE) has issued a number of guidelines for the use of pathology laboratory tests by GPs. Despite this, The Royal Co</span><span style="font-family:'Times New Roman'; font-size:12pt">llege of Pathologists has evidence that GPs’ use of</span><span style="font-family:'Times New Roman'; font-size:12pt"> these tests is highly variable. It is </span><span style="font-family:'Times New Roman'; font-size:12pt">too often not cost-effective and not always in the best interests of patients. The College thinks that more specialist pathologist input into GP requesting of tests c</span><span style="font-family:'Times New Roman'; font-size:12pt">an improve efficiency.  </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">4</span><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">              </span><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">Magnitude of variation</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:12pt">4.1</span><span style="font-family:'Times New Roman'; font-size:12pt">              </span><span style="font-family:'Times New Roman'; font-size:12pt">The College has collated evidence </span><span style="font-family:'Times New Roman'; font-size:12pt">that </span><span style="font-family:'Times New Roman'; font-size:12pt">includes studies </span><span style="font-family:'Times New Roman'; font-size:12pt">examining</span><span style="font-family:'Times New Roman'; font-size:12pt"> the use by GP practices</span><span style="font-family:'Times New Roman'; font-size:12pt"> of a number of tests including:</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 35.45pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:'Times New Roman'; font-size:12pt">4.2</span><span style="font-family:'Times New Roman'; font-size:12pt">              </span><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">HbA1C (diabetes)</span><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">:</span><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold"> </span><span style="font-family:'Times New Roman'; font-size:12pt; font-style:italic; font-weight:bold">O’Kane et al (Ann</span><span style="font-family:'Times New Roman'; font-size:12pt; font-style:italic; font-weight:bold">als of </span><span style="font-family:'Times New Roman'; font-size:12pt; font-style:italic; font-weight:bold">Clin</span><span style="font-family:'Times New Roman'; font-size:12pt; font-style:italic; font-weight:bold">ical</span><span style="font-family:'Times New Roman'; font-size:12pt; font-style:italic; font-weight:bold"> Biochem</span><span style="font-family:'Times New Roman'; font-size:12pt; font-style:italic; font-weight:bold">istry</span><span style="font-family:'Times New Roman'; font-size:12pt; font-style:italic; font-weight:bold"> 2011;48: 155-158</span><span style="font-family:'Times New Roman'; font-size:12pt; font-style:italic">)</span><span style="font-family:'Times New Roman'; font-size:12pt"> reported on the requests for  HbA1C (diabetes) and thyroid function tests in one year by 58 practices covering 284,609 patients in N</span><span style="font-family:'Times New Roman'; font-size:12pt">orthern</span><span style="font-family:'Times New Roman'; font-size:12pt"> Ireland. There was wide variability in test request rates and the practices with the highest requ</span><span style="font-family:'Times New Roman'; font-size:12pt">est rates for these tests were also the highest requesters for all other blood tests. </span></p><p style="margin:0pt 0pt 0pt 35.45pt; text-align:justify"><br /><span style="font-family:'Times New Roman'; font-size:12pt">There was no relationship between request rates for HbA1c and thyroid function and the known prevalence of diabetes and hypothyroidism respectively or with Quality and </span><span style="font-family:'Times New Roman'; font-size:12pt">Outcome Framework scores used through the </span><span style="font-family:'Times New Roman'; font-size:12pt">General Medical Services </span><span style="font-family:'Times New Roman'; font-size:12pt">contract to remunerate GP practices.</span></p><p style="margin:0pt 0pt 0pt 35.45pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 35.45pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:'Times New Roman'; font-size:12pt">4.3</span><span style="font-family:'Times New Roman'; font-size:12pt">              </span><span style="font-family:'Times New Roman'; font-size:12pt; font-style:italic; font-weight:bold">The Atlas of Variation Data</span><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold"> (not yet published)</span><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold"> </span><span style="font-family:'Times New Roman'; font-size:12pt">showed wide variation in the testing for and monitoring of ovarian cancer. </span><span style="font-family:'Times New Roman'; font-size:12pt">Carbohydrate antigen 125</span><span style="font-family:'Times New Roman'; font-size:12pt"> (CA-125)</span><span style="font-family:'Times New Roman'; font-size:12pt">, is</span><span style="font-family:'Times New Roman'; font-size:12pt"> </span><span style="font-family:'Times New Roman'; font-size:12pt">a protein found on the surface of ovarian cancer cells, and in some normal tissues</span><span style="font-family:'Times New Roman'; font-size:12pt">. It </span><span style="font-family:'Times New Roman'; font-size:12pt">is a </span><span style="font-family:'Times New Roman'; font-size:12pt">tumour marker for ovarian cancer. Traditionally, the C</span><span style="font-family:'Times New Roman'; font-size:12pt">A-</span><span style="font-family:'Times New Roman'; font-size:12pt">125 test has been used to monito</span><span style="font-family:'Times New Roman'; font-size:12pt">r treatment for ovarian cancer and to </span><span style="font-family:'Times New Roman'; font-size:12pt">detect whether cancer has returned after treatment has been completed. CA-125 is also elevated in association with other ovarian pathologies. Most of the use for both of these tests is in the confirmation of a suspected diagnosis and in the monitoring of t</span><span style="font-family:'Times New Roman'; font-size:12pt">he response to treatment. Specialist units are the main users of these tests, although some testing takes place in general practice. Data regarding use of this test is available for Primary Care Trust </span><span style="font-family:'Times New Roman'; font-size:12pt">(PCT) </span><span style="font-family:'Times New Roman'; font-size:12pt">level only</span><span style="font-family:'Times New Roman'; font-size:12pt">.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 35.45pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:'Times New Roman'; font-size:12pt">4.4</span><span style="font-family:'Times New Roman'; font-size:12pt">              </span><span style="font-family:'Times New Roman'; font-size:12pt">For PCTs in England, the estimat</span><span style="font-family:'Times New Roman'; font-size:12pt">ed rate of use for CA</span><span style="font-family:'Times New Roman'; font-size:12pt">-</span><span style="font-family:'Times New Roman'; font-size:12pt">125 tests ordered by GPs ranged from 0.11 to 9.0 per 1</span><span style="font-family:'Times New Roman'; font-size:12pt">,</span><span style="font-family:'Times New Roman'; font-size:12pt">000 practice population (80-fold variation). When the five PCTs with the highest estimated rates and the five PCTs with the lowest estimated </span><span style="font-family:'Times New Roman'; font-size:12pt">rates are excluded, the range </span><span style="font-family:'Times New Roman'; font-size:12pt">is </span><span style="font-family:'Times New Roman'; font-size:12pt">0.92-</span><span style="font-family:'Times New Roman'; font-size:12pt">8.4 per 1</span><span style="font-family:'Times New Roman'; font-size:12pt">,</span><span style="font-family:'Times New Roman'; font-size:12pt">000 practice population and the variation 9-fold. This is not due to differences in the prevalence of ovarian cancer. Some variation probably reflects differences in professional practice and commissioning prioritisation. </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 35.45pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:'Times New Roman'; font-size:12pt">4.5</span><span style="font-family:'Times New Roman'; font-size:12pt">              </span><span style="font-family:'Times New Roman'; font-size:12pt">The variation show</span><span style="font-family:'Times New Roman'; font-size:12pt">n for</span><span style="font-family:'Times New Roman'; font-size:12pt"> the CA-125 </span><span style="font-family:'Times New Roman'; font-size:12pt">test is seen across almost every test investigated in this study for the Atlas of Variation</span><span style="font-family:'Times New Roman'; font-size:12pt">.</span><span style="font-family:'Times New Roman'; font-size:12pt"> (The </span><span style="font-family:'Times New Roman'; font-size:12pt">Atlas of Variation Data has not yet been released for publication; </span><span style="font-family:'Times New Roman'; font-size:12pt">the data are obtained as part of a data quality audit and subject to stric</span><span style="font-family:'Times New Roman'; font-size:12pt">t governance protocols. Pathology messages to primary care were intercepted for a period of 23 days in June 2012. In all 1.8 million messages containing samples of 38 million test results for approximately </span><span style="font-family:'Times New Roman'; font-size:12pt">3 </span><span style="font-family:'Times New Roman'; font-size:12pt">million patients on 1,029 tests from 152 NHS lab</span><span style="font-family:'Times New Roman'; font-size:12pt">oratory sources were analysed</span><span style="color:#0070c0; font-family:'Times New Roman'; font-size:12pt">. </span><span style="font-family:'Times New Roman'; font-size:12pt">I</span><span style="font-family:'Times New Roman'; font-size:12pt">t</span><span style="font-family:'Times New Roman'; font-size:12pt">s data is intended to support local decision making to increase the value </span><span style="font-family:'Times New Roman'; font-size:12pt">that </span><span style="font-family:'Times New Roman'; font-size:12pt">a population receives from the resources spent on their healthcare</span><span style="font-family:'Times New Roman'; font-size:12pt">.</span><span style="font-family:'Times New Roman'; font-size:12pt">)</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 35.45pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:'Times New Roman'; font-size:12pt">4.6</span><span style="font-family:'Times New Roman'; font-size:12pt">              </span><span style="font-family:'Times New Roman'; font-size:12pt">Regardless of whether the variation reveals over or under requesting, this variation reflects inefficient use of NHS resource and may indicate overall unacceptable levels of health care. </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">5.</span><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">              </span><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">Pathology Demand Optimisation (PDO)</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:12pt">5.1</span><span style="font-family:'Times New Roman'; font-size:12pt">              </span><span style="font-family:'Times New Roman'; font-size:12pt">In 2013, the RCPath set</span><span style="font-family:'Times New Roman'; font-size:12pt"> up a Pathology Demand Optimisation (PDO) Group comprised of representatives from the major pathology disciplines, pathology societies, industry representatives, the National Pathology Programme and lay involvement. The purpose of this initiative was to al</span><span style="font-family:'Times New Roman'; font-size:12pt">low the major pathology stakeholders to work with already established leaders in the field of Laboratory Demand Management research to enable the development of specific Pathology Demand Management Guidance in the form of a toolkit of recommendations and a</span><span style="font-family:'Times New Roman'; font-size:12pt"> Minimum Retesting Interval (MRI) advisory strategy. </span><a name="_GoBack"></a></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:12pt">5.2</span><span style="font-family:'Times New Roman'; font-size:12pt">              </span><span style="font-family:'Times New Roman'; font-size:12pt">The </span><span style="font-family:'Times New Roman'; font-size:12pt">use of </span><span style="font-family:'Times New Roman'; font-size:12pt">MRIs is</span><span style="font-family:'Times New Roman'; font-size:12pt"> of vital importance and aim</span><span style="font-family:'Times New Roman'; font-size:12pt">s</span><span style="font-family:'Times New Roman'; font-size:12pt"> to define the minimum time interval whereby tests should be repeated</span><span style="font-family:'Times New Roman'; font-size:12pt">. This avoids</span><span style="font-family:'Times New Roman'; font-size:12pt"> unnecessary repeat testing – a common problem in secondary care with laboratory tests frequently being repeated whenever the patient crosses an interface of care</span><span style="font-family:'Times New Roman'; font-size:12pt">,</span><span style="font-family:'Times New Roman'; font-size:12pt"> such as a ward transfer. This is of increasing importance following commissioning and the in</span><span style="font-family:'Times New Roman'; font-size:12pt">herent risk of multiple pathology providers. While developments with the N</span><span style="font-family:'Times New Roman'; font-size:12pt">a</span><span style="font-family:'Times New Roman'; font-size:12pt">t</span><span style="font-family:'Times New Roman'; font-size:12pt">ional Laboratory Medicine Catalogue</span><span style="font-family:'Times New Roman'; font-size:12pt"> (NLMC)</span><span style="font-family:'Times New Roman'; font-size:12pt">, which should improve communication and transferability of pathology </span><span style="font-family:'Times New Roman'; font-size:12pt">results, will help, the availability of consensus, peer reviewed or </span><span style="font-family:'Times New Roman'; font-size:12pt">in some cases evidence based MRIs are essential.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 35.45pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:'Times New Roman'; font-size:12pt">5.3</span><span style="font-family:'Times New Roman'; font-size:12pt">              </span><span style="font-family:'Times New Roman'; font-size:12pt">When MRIs are defined</span><span style="font-family:'Times New Roman'; font-size:12pt">,</span><span style="font-family:'Times New Roman'; font-size:12pt"> they will need to be implemented.</span><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:12pt"> The benefits of defining and implementing MRI</span><span style="font-family:'Times New Roman'; font-size:12pt">s</span><span style="font-family:'Times New Roman'; font-size:12pt"> include:</span></p><p style="margin:0pt 0pt 0pt 42.55pt; text-align:justify; text-indent:-42.55pt"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:12pt; margin:0pt 0pt 0pt 45.97pt; padding-left:10.73pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:12pt">e</span><span style="font-family:'Times New Roman'; font-size:12pt">nsuring the appropriate tests are used</span></li><li style="font-family:Symbol; font-size:12pt; margin:0pt 0pt 0pt 45.97pt; padding-left:10.73pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:12pt">m</span><span style="font-family:'Times New Roman'; font-size:12pt">inimising/preventing unnecessary testing of </span><span style="font-family:'Times New Roman'; font-size:12pt">patients</span></li><li style="font-family:Symbol; font-size:12pt; margin:0pt 0pt 0pt 45.97pt; padding-left:10.73pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:12pt">r</span><span style="font-family:'Times New Roman'; font-size:12pt">educing inappropriate testing </span><span style="font-family:'Times New Roman'; font-size:12pt">to </span><span style="font-family:'Times New Roman'; font-size:12pt">reduce costs to the National Health Service (NHS)</span></li><li style="font-family:Symbol; font-size:12pt; margin:0pt 0pt 0pt 45.97pt; padding-left:10.73pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:12pt">r</span><span style="font-family:'Times New Roman'; font-size:12pt">educing processing workload in stretched laboratories</span></li></ul><p style="margin:0pt 0pt 0pt 17.85pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 35.45pt; text-align:justify; text-indent:-35.45pt"><span style="font-family:'Times New Roman'; font-size:12pt">5.4</span><span style="font-family:'Times New Roman'; font-size:12pt">              </span><span style="font-family:'Times New Roman'; font-size:12pt">In summary, Pathology Demand Optimisation is of vital importance to </span><span style="font-family:'Times New Roman'; font-size:12pt">ensure the right test is done to</span><span style="font-family:'Times New Roman'; font-size:12pt"> th</span><span style="font-family:'Times New Roman'; font-size:12pt">e right patient at the right time, ensuring the </span><span style="font-family:'Times New Roman'; font-size:12pt">best </span><span style="font-family:'Times New Roman'; font-size:12pt">use of scarce NHS resource and the best possible outcomes for patients. The RCPath continues to drive this process through initiatives such as the NLMC </span><span style="font-family:'Times New Roman'; font-size:12pt">to improve </span><span style="font-family:'Times New Roman'; font-size:12pt">the</span><span style="font-family:'Times New Roman'; font-size:12pt"> interoperability (sharing) of p</span><span style="font-family:'Times New Roman'; font-size:12pt">a</span><span style="font-family:'Times New Roman'; font-size:12pt">thology test results and the Pathology Demand Optimisation</span><span style="font-family:'Times New Roman'; font-size:12pt"> guidance </span><span style="font-family:'Times New Roman'; font-size:12pt">to provide </span><span style="font-family:'Times New Roman'; font-size:12pt">a c</span><span style="font-family:'Times New Roman'; font-size:12pt">onsistent approach to managing requests for pathology testing</span><span style="font-family:'Times New Roman'; font-size:12pt">.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt">.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">6.</span><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">              </span><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">Reconfiguration</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:12pt">6.1</span><span style="font-family:'Times New Roman'; font-size:12pt">              </span><span style="font-family:'Times New Roman'; font-size:12pt">The RCPath</span><span style="font-family:'Times New Roman'; font-size:12pt"> </span><span style="font-family:'Times New Roman'; font-size:12pt">supports the development of consolidated networks for pathology </span><span style="font-family:'Times New Roman'; font-size:12pt">services t</span><span style="font-family:'Times New Roman'; font-size:12pt">o</span><span style="font-family:'Times New Roman'; font-size:12pt"> help improve the quality and safety of patient care as outlined in </span><span style="font-family:'Times New Roman'; font-size:12pt; font-style:italic">The Report of the Second Phase of the Review of NHS Pathology Services in England</span><span style="font-family:'Times New Roman'; font-size:12pt">, December 2008</span><span style="font-family:'Times New Roman'; font-size:12pt"> (</span><span style="font-family:'Times New Roman'; font-size:12pt">T</span><span style="font-family:'Times New Roman'; font-size:12pt">he Carter Review). </span><span style="font-family:'Times New Roman'; font-size:12pt">This said that, “</span><span style="font-family:'Times New Roman'; font-size:12pt">Service consolidation is necessary to transform path</span><span style="font-family:'Times New Roman'; font-size:12pt">ology services so that they can respond swiftly to the challenges presented by innovation …, system reform across the NHS and reform of the workforce. </span><span style="font-family:'Times New Roman'; font-size:12pt">Consolidation provides </span><span style="font-family:'Times New Roman'; font-size:12pt">the means</span><span style="font-family:'Times New Roman'; font-size:12pt"> of improving service quality, responsiveness and cost-effectiveness by </span><span style="font-family:'Times New Roman'; font-size:12pt">e</span><span style="font-family:'Times New Roman'; font-size:12pt">nabling resources</span><span style="font-family:'Times New Roman'; font-size:12pt"> to be reinvested in pathology services. Reinvestment of savings is essential to</span><span style="font-family:'Times New Roman'; font-size:12pt"> </span><span style="font-family:'Times New Roman'; font-size:12pt">deliver and assure service quality, and to support the rapid adoption of innovative new</span><span style="font-family:'Times New Roman'; font-size:12pt"> </span><span style="font-family:'Times New Roman'; font-size:12pt">technology and new approaches to the delivery of pathology services.</span><span style="font-family:'Times New Roman'; font-size:12pt">”</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:12pt">6.2</span><span style="font-family:'Times New Roman'; font-size:12pt">              </span><span style="font-family:'Times New Roman'; font-size:12pt">The College thinks that </span><span style="font-family:'Times New Roman'; font-size:12pt">the </span><span style="font-family:'Times New Roman'; font-size:12pt">picture today is radically different from Lord Carter’s vis</span><span style="font-family:'Times New Roman'; font-size:12pt">i</span><span style="font-family:'Times New Roman'; font-size:12pt">on; far from a service that is integrated and patient-centred the commissioning process </span><span style="font-family:'Times New Roman'; font-size:12pt">has so fare </span><span style="font-family:'Times New Roman'; font-size:12pt">been driven by </span><span style="font-family:'Times New Roman'; font-size:12pt">financial</span><span style="font-family:'Times New Roman'; font-size:12pt"> considerations. </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:12pt">6.3</span><span style="font-family:'Times New Roman'; font-size:12pt">              </span><span style="font-family:'Times New Roman'; font-size:12pt">The College has warned that that there will be a detrimental effect on services from failed reconfigurations, as well as </span><span style="font-family:'Times New Roman'; font-size:12pt">the </span><span style="font-family:'Times New Roman'; font-size:12pt">high cost</span><span style="font-family:'Times New Roman'; font-size:12pt">s</span><span style="font-family:'Times New Roman'; font-size:12pt"> incurred. Using information from a Freedom of Information request, the </span><span style="font-family:'Times New Roman'; font-size:12pt; font-style:italic">Health Service Journal</span><span style="font-family:'Times New Roman'; font-size:12pt"> (HSJ) put at £2</span><span style="font-family:'Times New Roman'; font-size:12pt"> </span><span style="font-family:'Times New Roman'; font-size:12pt">m</span><span style="font-family:'Times New Roman'; font-size:12pt">illion</span><span style="font-family:'Times New Roman'; font-size:12pt"> th</span><span style="font-family:'Times New Roman'; font-size:12pt">e central costs of three regional pathology reorganisations in th</span><span style="font-family:'Times New Roman'; font-size:12pt">e former NHS Midlands and East Strategic Health a</span><span style="font-family:'Times New Roman'; font-size:12pt">uthority (</span><span style="font-family:'Times New Roman'; font-size:12pt; font-style:italic">HSJ</span><span style="font-family:'Times New Roman'; font-size:12pt"> 30 August 2013).</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><p style="font-size:12pt; line-height:115%; margin:0pt 0pt 10pt 36pt; text-align:justify; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:12pt">6.4</span><span style="font-family:'Times New Roman'; font-size:12pt">              </span><span style="font-family:'Times New Roman'; font-size:12pt">Most recently, a </span><span style="font-family:'Times New Roman'; font-size:12pt">£500</span><span style="font-family:'Times New Roman'; font-size:12pt"> </span><span style="font-family:'Times New Roman'; font-size:12pt">m</span><span style="font-family:'Times New Roman'; font-size:12pt">illion</span><span style="font-family:'Times New Roman'; font-size:12pt"> pathology reorganisation </span><span style="font-family:'Times New Roman'; font-size:12pt">in </span><span style="font-family:'Times New Roman'; font-size:12pt">the West</span><span style="font-family:'Times New Roman'; font-size:12pt"> Midlands </span><span style="font-family:'Times New Roman'; font-size:12pt">collapsed after </span><span style="font-family:'Times New Roman'; font-size:12pt">the </span><span style="font-family:'Times New Roman'; font-size:12pt">commissioners opted to abandon a controversial procurement exercise</span><span style="font-family:'Times New Roman'; font-size:12pt"> (</span><span style="font-family:'Times New Roman'; font-size:12pt; font-style:italic">H</span><span style="font-family:'Times New Roman'; font-size:12pt; font-style:italic">SJ</span><span style="font-family:'Times New Roman'; font-size:12pt">, 16 September 2013).</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:12pt">6.5</span><span style="font-family:'Times New Roman'; font-size:12pt">              </span><span style="font-family:'Times New Roman'; font-size:12pt">Other </span><span style="font-family:'Times New Roman'; font-size:12pt">drains</span><span style="font-family:'Times New Roman'; font-size:12pt"> on resources when there is uncertainty over </span><span style="font-family:'Times New Roman'; font-size:12pt">reconfiguration include</span><span style="font-family:'Times New Roman'; font-size:12pt">:</span><span style="font-family:'Times New Roman'; font-size:12pt"> wasted staff time; lower productivity and </span><span style="font-family:'Times New Roman'; font-size:12pt">poor </span><span style="font-family:'Times New Roman'; font-size:12pt">staff morale; problems retain</span><span style="font-family:'Times New Roman'; font-size:12pt">ing and </span><span style="font-family:'Times New Roman'; font-size:12pt">recruiting </span><span style="font-family:'Times New Roman'; font-size:12pt">staff</span><span style="font-family:'Times New Roman'; font-size:12pt"> and </span><span style="font-family:'Times New Roman'; font-size:12pt">the resulting need to recruit from agencies. All of these issues risk affecting affect the service provided and the quality of patient care.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt">6.6</span><span style="font-family:'Times New Roman'; font-size:12pt">              </span><span style="font-family:'Times New Roman'; font-size:12pt">The College is </span><span style="font-family:'Times New Roman'; font-size:12pt">working to address some of these concerns with the </span><span style="font-family:'Times New Roman'; font-size:12pt">production of:</span><br /><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:12pt; margin:0pt 0pt 0pt 53.07pt; padding-left:3.63pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:12pt">a reconfiguration risk register</span><span style="font-family:'Times New Roman'; font-size:12pt"> to assist pathology providers by identifying common pitfalls  when reorganising pathology services;</span><span style="font-family:'Times New Roman'; font-size:12pt"> </span></li></ul><p style="margin:0pt 0pt 0pt 24.55pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:12pt; margin:0pt 0pt 0pt 53.07pt; padding-left:3.63pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:12pt">the </span><span style="font-family:'Times New Roman'; font-size:12pt">development and roll out of Key </span><span style="font-family:'Times New Roman'; font-size:12pt">Performance</span><span style="font-family:'Times New Roman'; font-size:12pt"> Indicators </span><span style="font-family:'Times New Roman'; font-size:12pt">(KPIs) </span><span style="font-family:'Times New Roman'; font-size:12pt">to provide quality standards that can be be</span><span style="font-family:'Times New Roman'; font-size:12pt">nchmarked; </span><span style="font-family:'Times New Roman'; font-size:12pt">KPIs </span><span style="font-family:'Times New Roman'; font-size:12pt">provide evidence of conformity with standards of accreditation and, through discussion with </span><span style="font-family:'Times New Roman'; font-size:12pt">service </span><span style="font-family:'Times New Roman'; font-size:12pt">users, will facilitate demand management and support a clinically effective service. The collection of KPI data during Clinical Pathology </span><span style="font-family:'Times New Roman'; font-size:12pt">Accreditation</span><span style="font-family:'Times New Roman'; font-size:12pt"> visits will be piloted by the United Kingdom </span><span style="font-family:'Times New Roman'; font-size:12pt">Accreditation</span><span style="font-family:'Times New Roman'; font-size:12pt"> Service from October 2013.</span></li></ul><p style="margin:0pt 0pt 0pt 24.55pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:12pt; margin:0pt 0pt 0pt 53.07pt; padding-left:3.63pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:12pt">the provision </span><span style="font-family:'Times New Roman'; font-size:12pt">of independent clinical advice</span><span style="font-family:'Times New Roman'; font-size:12pt">. This can provide in-depth analysis; benchmarking against other services and assessment of outputs against other services. </span><span style="font-family:'Times New Roman'; font-size:12pt">It can </span><span style="font-family:'Times New Roman'; font-size:12pt">also offer a valuable over-view </span><span style="font-family:'Times New Roman'; font-size:12pt">of reconfiguration projects, contrasting the aspirations of the project with progress on the ground.</span><br /><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></li></ul><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:12pt">6.7</span><span style="font-family:'Times New Roman'; font-size:12pt">              </span><span style="font-family:'Times New Roman'; font-size:12pt">It </span><span style="font-family:'Times New Roman'; font-size:12pt">is vital</span><span style="font-family:'Times New Roman'; font-size:12pt"> that pathology services are designed and built around patient need. As a </span><span style="font-family:'Times New Roman'; font-size:12pt">major clinical service dri</span><span style="font-family:'Times New Roman'; font-size:12pt">ving most healthcare decisions, pathology is the keystone of diagnoses and treatment. </span><span style="font-family:'Times New Roman'; font-size:12pt">During this period of large scale pathology reconfiguration and commissioning of services to multiple providers it is vital that pathology services are efficient and reta</span><span style="font-family:'Times New Roman'; font-size:12pt">in sufficient quality and consistency across the NHS. </span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:12pt; font-style:italic">November 2013</span></p><p style="margin:0pt"><span style="font-family:Arial; font-size:11pt">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:Arial; font-size:11pt">&#xa0;</span></p></div></body></html>